Back Hepatitis B Hepatitis B Topics HBV Treatment

AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern

Treatment of chronic hepatitis B with nucleoside/nucleotide analogs including lamivudine (Epivir-HBV) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection, according to studies presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) and published in the Journal of the American Medical Association. alt

Read more:

AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss

Tenofovir (Viread) continues to be safe and highly effective for treating chronic hepatitis B through 8 years of follow-up, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this week in Boston. Another study showed minimal bone loss among tenofovir-treated patients using the FRAX method. alt

Read more:

Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis

Antiviral drugs including entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and tenofovir (Viread) are generally well-tolerated and effective against hepatitis B virus (HBV) in people with liver cirrhosis, and may lower mortality even among patients with severe decompensated cirrhosis, according to 2 recently published studies.alt

Read more:

Coverage of the 2012 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

HIVandHepatitis.com AASLD 2012 conference section

11/13/12

alt

Registry Data Show Hepatitis B Medications Appear Safe during Pregnancy

An analysis of data from the Antiretroviral Pregnancy Registry found no evidence that pregnant women's use of drugs to treat chronic hepatitis B -- including lamivudine (Epivir) and tenofovir (Viread) -- is associated with birth defects, according to a report in the November 2012 Journal of Hepatology. alt

Read more: